Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate Sitravatinib, an oral small molecular receptor
tyrosine kinase inhibitor, for the treatment of advanced liposarcoma.